Alterity Therapeutics (ATHE) Non-Current Assets (2009 - 2025)
Alterity Therapeutics (ATHE) posted quarterly Non-Current Assets of $62953.8 for Q4 2025, down 16.83% year-over-year from $75696.1 in Q4 2024, and down 36.65% quarter-over-quarter from $99378.6 in Q2 2025.
Alterity Therapeutics (ATHE) Non-Current Assets (2009 - 2025) Analysis & Trends
Alterity Therapeutics' Non-Current Assets history runs 17 years deep, the most recent figure standing at $62953.8 for Q4 2025.
- In Q4 2025, Non-Current Assets fell 16.83% year-over-year to $62953.8; the TTM figure through Dec 2025 stood at $361189.0 (up 8.99% YoY), while the FY2025 annual figure was $99378.6, down 19.31% from the prior year.
- Non-Current Assets for Q4 2025 stood at $62953.8, down from $99378.6 in the prior quarter.
- The five-year high for Non-Current Assets was $156520.4 in Q2 2022, with the low at $2688.6 in Q2 2023.
- The 5-year median for Non-Current Assets is $87537.4 (2024), against an average of $88931.2.
- The sharpest annual moves came in 2023 and 2024: Non-Current Assets tumbled 98.28% in 2023, then jumped 4480.79% in 2024.
- Alterity Therapeutics' Non-Current Assets stood at $49763.2 in 2021, then jumped by 130.58% to $114742.3 in 2022, then rose by 13.18% to $129861.5 in 2023, then slumped by 41.71% to $75696.1 in 2024, then decreased by 16.83% to $62953.8 in 2025.
- Business Quant data shows ATHE's Non-Current Assets at $62953.8 in Q4 2025, $99378.6 in Q2 2025, and $75696.1 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Alterity Therapeutics | 48.56 Mn | 16.26 Mn | - | 62,953.78 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 62,953.78 |
| Jun 30, 2025 | 99,378.58 |
| Dec 31, 2024 | 75,696.13 |
| Jun 30, 2024 | 123,160.47 |
| Dec 31, 2023 | 129,861.53 |
| Jun 30, 2023 | 2,688.63 |
| Dec 31, 2022 | 114,742.29 |
| Jun 30, 2022 | 156,520.39 |
| Dec 31, 2021 | 49,763.16 |
| Jun 30, 2021 | 74,547.50 |
| Dec 31, 2020 | 27,943.64 |
| Jun 30, 2020 | 46,776.71 |
| Dec 31, 2019 | 80,161.29 |
| Jun 30, 2019 | 34,146.62 |
| Dec 31, 2018 | 10.15 Bn |
| Jun 30, 2018 | 54,069.09 |
| Dec 31, 2017 | 19,384.39 |
| Jun 30, 2017 | 18.99 Bn |
| Dec 31, 2016 | 59,903.90 |
| Jun 30, 2016 | 25.18 Bn |